Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Salix Pharmaceuticals Ltd -- Ignore unavailable to you. Want to Upgrade?

To: VIXandMore who wrote (2)	12/9/2003 9:30:41 PM
From: VIXandMore	Respond to of 5

Salix Pharmaceuticals Selected as "Pick of the Week" - Salix to be Featured on MSNBC on December 10, 2003 RALEIGH, N.C.--(BUSINESS WIRE)--Dec. 9, 2003--Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP - News) today announced that the company has been selected as the featured company on the "Terry Bradshaw's Pick of the Week" television series. Salix will be featured on the MSNBC network on Wednesday, December 10, 2003 between 7:45 a.m. and 8:15 a.m. ET. The "Pick of the Week" series recognizes up and coming companies in various fields that reflect the grit and determination required to succeed in extraordinary times. "We are delighted to be selected as the "Pick of the Week" by Terry Bradshaw and his organization, commented Carolyn Logan, President and Chief Executive Officer, Salix Pharmaceuticals, Inc. "Over the course of the past three years the Company has been diligent in its quest to become the leading specialty pharmaceutical company providing products to gastroenterologists and their patients in the United States. Internally, we have been well aware of the dedication and hard work all of our employees have extended toward our goal. It is extremely gratifying to have a third party recognize and value our efforts. Our determination and effort are paying dividends. In a relatively short span of time, we have succeeded in building a thriving business with a solid first marketed product in COLAZAL®, a second product under review at the FDA for marketing approval and a growing pipeline of potential additional products. We look forward to continued success with anticipation and confidence."